CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 21 - 30 of 886
Study Number Lead Group Study Title CIRB Study Status
A031704 Alliance PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Adult CIRB - Late Phase Emphasis Available to Open
10010 ETCTN A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent; Persistent or Metastatic Cervical Cancer Adult CIRB - Early Phase Emphasis Available to Open
10371 ETCTN A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response Adult CIRB - Early Phase Emphasis Available to Open
10405 ETCTN Phase I Trial of BAY 1895344 ATR Inhibitor Combined with Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma Adult CIRB - Early Phase Emphasis Available to Open
RTOG-1010 RTOG A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma Adult CIRB - Late Phase Emphasis Available to Open
AALL08P1 COG Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study Pediatric CIRB Available to Open
NRG-CC003 NRG Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer Cancer Prevention and Control CIRB Available to Open
10089 ETCTN A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Adult CIRB - Early Phase Emphasis Available to Open
9899 ETCTN A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) inhibitor AT7519M in patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10219 ETCTN Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Adult CIRB - Early Phase Emphasis Available to Open
Displaying 21 - 30 of 886